MF Researcher Database

研究者一覧

詳細

今村　知世Imamura Chiyo

■所属部署名先端がん治療研究所
■職名准教授
Last Updated :2023/07/12

研究者情報

基本情報

プロフィール情報

  • 氏名

    今村　知世, Imamura Chiyo

所属

  • 先端がん治療研究所, 准教授

施設

  • 旗の台校舎

学位

  • 博士(薬学), 熊本大学, 2000年03月

研究キーワード

  • 臨床薬理、個別化医療

所属学協会

  • 日本薬学会，日本医療薬学会，日本臨床薬理学会， 日本TDM学会， 日本薬物動態学会，日本癌治療学会，日本臨床腫瘍学会，日本肺癌学会， 日本がんサポーティブケア学会，日本乳癌学会，American Society of Clinical Oncology (ASCO)，American Society for Clinical Pharmacology and Therapeutics (ASCPT), International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)

学術貢献活動

  • 日本医療薬学会：代議員，がん専門薬剤師抗がん薬プロフィール小委員会委員． 日本臨床薬理学会：評議員． 日本TDM学会：評議員，TDMガイドライン策定委員会委員，国際交流委員会委員． 日本癌治療学会：代議員，制吐薬適正使用ガイドライン改訂ワーキンググループ委員，がん診療ガイドライン統括・連絡委員会委員（医薬品プロフィール担当）． 日本臨床腫瘍学会：協議員，教育企画部会委員． 日本肺癌学会：ガイドライン検討委員会薬物療法及び集学的治療小委員会委員． 日本乳癌学会：学術委員会委員． 日本がんサポーティブケア学会：評議員，国際委員会委員． 静岡県立静岡がんセンター企業治験倫理審査委員会委員．

業績

論文

  • Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients., Hirotsugu Kenmotsu; Chiyo K Imamura; Takahisa Kawamura; Takuya Oyakawa; Shota Omori; Kazuhisa Nakashima; Kazushige Wakuda; Akira Ono; Tetsuhiko Taira; Tateaki Naito; Haruyasu Murakami; Nobuyuki Yamamoto; Toshiaki Takahashi; Yusuke Tanigawara, Cancer chemotherapy and pharmacology, 2022年07月
  • Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients., Hirotsugu Kenmotsu; Chiyo K Imamura; Takahisa Kawamura; Takuya Oyakawa; Shota Omori; Kazuhisa Nakashima; Kazushige Wakuda; Akira Ono; Tetsuhiko Taira; Tateaki Naito; Haruyasu Murakami; Nobuyuki Yamamoto; Toshiaki Takahashi; Yusuke Tanigawara, Cancer chemotherapy and pharmacology, 2022年07月
  • Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials., Eisuke Booka; Chiyo K Imamura; Masashi Takeuchi; Hirofumi Kawakubo; Hiroya Takeuchi; Yusuke Tanigawara; Yuko Kitagawa; Narikazu Boku, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022年03月
  • Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials., Eisuke Booka; Chiyo K Imamura; Masashi Takeuchi; Hirofumi Kawakubo; Hiroya Takeuchi; Yusuke Tanigawara; Yuko Kitagawa; Narikazu Boku, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022年03月
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy, Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K. Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda, Medicine, 100(23):e25774 - e25774, 2021年06月
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy, Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K. Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda, Medicine, 100(23):e25774 - e25774, 2021年06月
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy, Yuya Hirasawa; Kiyoshi Yoshimura; Hiroto Matsui; Yutaro Kubota; Hiroo Ishida; Jun Arai; Masashi Sakaki; Nao Oguro; Midori Shida; Makoto Taniguchi; Kazuyuki Hamada; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Ryotaro Ohkuma; Takehiko Sambe; Atsushi Horiike; Chiyo K. Imamura; Eisuke Shiozawa; Satoshi Wada; Junji Tsurutani; Sanju Iwamoto; Naoki Uchida; Yuji Kiuchi; Genshu Tate; Shinichi Kobayashi; Takuya Tsunoda, Medicine, 100(23):e25774 - e25774, 2021年06月
  • Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations., KO Ryo;SHUKUYA Takehito;IMAMURA Chiyo K.;TOKITO Takaaki;SHIMADA Naoko;KOYAMA Ryo;YAMADA Kazuhiko;ISHII Hidenobu;AZUMA Koichi;TAKAHASHI Kazuhisa, Transl Lung Cancer Res, 10(1):183 - 192, 2021年01月, 原著, 査読あり, DOI:10.21037/tlcr-20-824
  • Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis., AOGI Kenjiro;TAKEUCHI Hideki;SAEKI Toshiaki;AIBA Keisuke;TAMURA Kazuo;IINO Keiko;IMAMURA Chiyo K.;OKITA Kenji;KAGAMI Yoshikazu;TANAKA Ryuhei;NAKAGAWA Kazuhiko;FUJII Hirofumi;BOKU Narikazu;WADA Makoto;AKECHI Tatsuo;IIHARA Hirotoshi;OHTANI Shoichiro;OKUYAMA Ayako;OZAWA Keiko;KIM Yong-II;SASAKI Hidenori;SHIMA Yasuo;TAKEDA Masayuki;NAGASAKI Eijiro;NISHIDATE Toshihiko;HIGASHI Takehiro;HIRATA Kouichi, Int J Clin Oncol, 26(1):1 - 17, 2021年01月, 原著, 査読あり
  • Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application., TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;TAKEUCHI Hiroya;MIZUKAMI Takuro;KAWAKAMI Takeshi;FUNAKOSHI Taro;WAKUDA Kazushige;AOKI Yu;HAMAMOTO Yasuo;KITAGO Minoru;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, Cancer Sci, :e, 2020年12月, 原著, 査読あり
  • Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia., INOUE Akiko;IMAMURA Chiyo K.;SHIMADA Hiroyuki;KATAYAMA Daisuke;URABE Keisuke;SUZUKI Ryo;TAKITANI Kimitaka;ASHIDA Akira, J Pediatr Pharmacol Ther, 25(8):742 - 745, 2020年11月, 原著, 査読あり
  • Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group., HIRATA Kenro;HAMAMOTO Yasuo;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;YAMAZAKI Kentaro;HIRONAKA Shuichi;MURO Kei, BMC Cancer, 20(1):548, 2020年06月, 原著, 査読あり
  • A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide., MATSUMOTO Koji;TAKAHASHI Masato;SATO Kazuhiko;OSAKI Akihiko;TAKANO Toshimi;NAITO Yoichi;MATSUURA Kazuo;AOGI Kenjiro;FUJIWARA Kimiko;TAMURA Kenji;BABA Motoi;TOKUNAGA Shinya;HIRANO Gen;IMOTO Shigeru;MIYAZAKI Chieko;YANAGIHARA Kazuhiro;IMAMURA Chiyo K.;CHIBA Yasutaka;SAEKI Toshiaki, Cancer Med, 9(10):3319 - 3327, 2020年05月, 原著, 査読あり
  • 小児がん治療における臨床薬理, 今村　知世, 小児外科, 52(5):454 - 459, 2020年05月
  • Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity., KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, Cancer Chemother Pharmacol, 85(3):605 - 614, 2020年03月, 原著, 査読あり
  • A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T, Clinical colorectal cancer, 19(1):13 - 21, 2020年03月
  • A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T, Clinical colorectal cancer, 19(1):13 - 21, 2020年03月
  • A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T, Clinical colorectal cancer, 19(1):13 - 21, 2020年03月
  • CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., Kenji Tamura; Chiyo K Imamura; Toshimi Takano; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(6):558 - 566, 2020年02月
  • CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., Kenji Tamura; Chiyo K Imamura; Toshimi Takano; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(6):558 - 566, 2020年02月
  • CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., Kenji Tamura; Chiyo K Imamura; Toshimi Takano; Shigehira Saji; Takeharu Yamanaka; Kan Yonemori; Masato Takahashi; Junji Tsurutani; Reiki Nishimura; Kazuhiko Sato; Akira Kitani; Naoto T Ueno; Taisei Mushiroda; Michiaki Kubo; Yasuhiro Fujiwara; Yusuke Tanigawara, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(6):558 - 566, 2020年02月
  • Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., Kentaro Yamazaki; Shigemi Matsumoto; Chiyo K Imamura; Chiemi Yamagiwa; Ayaka Shimizu; Takayuki Yoshino, Japanese journal of clinical oncology, 50(2):122 - 128, 2020年02月
  • Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., Kentaro Yamazaki; Shigemi Matsumoto; Chiyo K Imamura; Chiemi Yamagiwa; Ayaka Shimizu; Takayuki Yoshino, Japanese journal of clinical oncology, 50(2):122 - 128, 2020年02月
  • Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., Kentaro Yamazaki; Shigemi Matsumoto; Chiyo K Imamura; Chiemi Yamagiwa; Ayaka Shimizu; Takayuki Yoshino, Japanese journal of clinical oncology, 50(2):122 - 128, 2020年02月
  • CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., TAMURA Kenji;IMAMURA Chiyo K.;TAKANO Toshimi;SAJI Shigehira;YAMANAKA Takeharu;YONEMORI Kan;TAKAHASHI Masato;TSURUTANI Junji;NISHIMURA Reiki;SATO Kazuhiko;KITANI Akira;UENO Naoto T.;MUSHIRODA Taisei;KUBO Michiaki;FUJIWARA Yasuhiro;TANIGAWARA Yusuke, J Clin Oncol, :JCO1901412, 2019年12月, 原著, 査読あり
  • Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., YAMAZAKI Kentaro;MATSUMOTO Shigemi;IMAMURA Chiyo K.;YAMAGIWA Chiemi;SHIMIZU Ayaka;YOSHINO Takayuki, Jpn J Clin Oncol, :e, 2019年10月, 原著, 査読あり
  • A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., SUZUKI Takeshi;SUKAWA Yasutaka;IMAMURA Chiyo K.;MASUISHI Toshiki;SATAKE Hironaga;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, Clin Colorectal Cancer, :e, 2019年10月, 原著, 査読あり
  • The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV., AKAMATSU Hiroaki;NINOMIYA Kiichiro;KENMOTSU Hirotsugu;MORISE Masahiro;DAGA Haruko;GOTO Yasushi;KOZUKI Toshiyuki;MIURA Satoru;SASAKI Takaaki;TAMIYA Akihiro;TERAOKA Shunsuke;TSUBATA Yukari;YOSHIOKA Hiroshige;HATTORI Yoshihiro;IMAMURA Chiyo K.;KATSUYA Yuki;MATSUI Reiko;MINEGISHI Yuji;MIZUGAKI Hidenori;NOSAKI Kaname;OKUMA Yusuke;SAKAMOTO Setsuko;SONE Takashi;TANAKA Kentaro;UMEMURA Shigeki;YAMANAKA Takeharu;AMANO Shinsuke;HASEGAWA Kazuo;MORITA Satoshi;NAKAJIMA Kazuko;MAEMONDO Makoto;SETO Takashi;YAMAMOTO Nobuyuki, Int J Clin Oncol, 24(7):731 - 770, 2019年07月, 原著, 査読あり
  • Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties, Imamura K. Chiyo, Drug Metab Pharmacokinet, 34(1):14 - 18, 2019年02月
  • Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties, Imamura K. Chiyo, Drug Metab Pharmacokinet, 34(1):14 - 18, 2019年02月
  • Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties, Imamura K. Chiyo, Drug Metab Pharmacokinet, 34(1):14 - 18, 2019年02月
  • Individualized dosing of axitinib based on first-dose area under the concentration-time curve for metastatic renal-cell carcinoma., Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T, Clinical genitourinary cancer, 17(1):e1 - e11, 2019年02月
  • Individualized dosing of axitinib based on first-dose area under the concentration-time curve for metastatic renal-cell carcinoma., Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T, Clinical genitourinary cancer, 17(1):e1 - e11, 2019年02月
  • Individualized dosing of axitinib based on first-dose area under the concentration-time curve for metastatic renal-cell carcinoma., Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T, Clinical genitourinary cancer, 17(1):e1 - e11, 2019年02月
  • Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen., Toshimichi Nakamura; Kota Toshimoto; Wooin Lee; Chiyo K Imamura; Yusuke Tanigawara; Yuichi Sugiyama, CPT: pharmacometrics & systems pharmacology, 7(7):474 - 482, 2018年07月
  • Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen., Toshimichi Nakamura; Kota Toshimoto; Wooin Lee; Chiyo K Imamura; Yusuke Tanigawara; Yuichi Sugiyama, CPT: pharmacometrics & systems pharmacology, 7(7):474 - 482, 2018年07月
  • Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen., Toshimichi Nakamura; Kota Toshimoto; Wooin Lee; Chiyo K Imamura; Yusuke Tanigawara; Yuichi Sugiyama, CPT: pharmacometrics & systems pharmacology, 7(7):474 - 482, 2018年07月
  • Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer., Teruo Yamauchi; Jose Rodrigo Espinosa Fernandez; Chiyo K Imamura; Hideko Yamauchi; Hiromitsu Jinno; Maiko Takahashi; Yuko Kitagawa; Seigo Nakamura; Bora Lim; Savitri Krishnamurthy; James M Reuben; Diane Liu; Debasish Tripathy; Helen Chen; Naoko Takebe; Hideyuki Saya; Naoto T Ueno, Oncotarget, 9(6):6872 - 6882, 2018年01月
  • Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer., Teruo Yamauchi; Jose Rodrigo Espinosa Fernandez; Chiyo K Imamura; Hideko Yamauchi; Hiromitsu Jinno; Maiko Takahashi; Yuko Kitagawa; Seigo Nakamura; Bora Lim; Savitri Krishnamurthy; James M Reuben; Diane Liu; Debasish Tripathy; Helen Chen; Naoko Takebe; Hideyuki Saya; Naoto T Ueno, Oncotarget, 9(6):6872 - 6882, 2018年01月
  • Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer., Teruo Yamauchi; Jose Rodrigo Espinosa Fernandez; Chiyo K Imamura; Hideko Yamauchi; Hiromitsu Jinno; Maiko Takahashi; Yuko Kitagawa; Seigo Nakamura; Bora Lim; Savitri Krishnamurthy; James M Reuben; Diane Liu; Debasish Tripathy; Helen Chen; Naoko Takebe; Hideyuki Saya; Naoto T Ueno, Oncotarget, 9(6):6872 - 6882, 2018年01月
  • The effects of advanced age and serum α1-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients, Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y, British Journal of Clinical Pharmacology, 83(11):2416 - 2425, 2017年11月
  • The effects of advanced age and serum α1-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients, Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y, British Journal of Clinical Pharmacology, 83(11):2416 - 2425, 2017年11月
  • The effects of advanced age and serum α1-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients, Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y, British Journal of Clinical Pharmacology, 83(11):2416 - 2425, 2017年11月
  • Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer, Otsubo K; Nosaki K; Imamura CK; Ogata H; Fujita A; Sakata S; Hirai F; Toyokawa G; Iwama E; Harada T; Seto T; Takenoyama M; Ozaki T; Mushiroda T; Inada M; Kishimoto J; Tsuchihashi K; Suina K; Nagano O; Saya H; Nakanishi Y; Okamoto I, Cancer Sci, 108(9):1843 - 1849, 2017年09月
  • Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer, Otsubo K; Nosaki K; Imamura CK; Ogata H; Fujita A; Sakata S; Hirai F; Toyokawa G; Iwama E; Harada T; Seto T; Takenoyama M; Ozaki T; Mushiroda T; Inada M; Kishimoto J; Tsuchihashi K; Suina K; Nagano O; Saya H; Nakanishi Y; Okamoto I, Cancer Sci, 108(9):1843 - 1849, 2017年09月
  • Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer, Otsubo K; Nosaki K; Imamura CK; Ogata H; Fujita A; Sakata S; Hirai F; Toyokawa G; Iwama E; Harada T; Seto T; Takenoyama M; Ozaki T; Mushiroda T; Inada M; Kishimoto J; Tsuchihashi K; Suina K; Nagano O; Saya H; Nakanishi Y; Okamoto I, Cancer Sci, 108(9):1843 - 1849, 2017年09月
  • Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12), Kayoko Yoshida; Chiyo K. Imamura; Kanako Hara; Mayumi Mochizuki; Yusuke Tanigawara, METABOLOMICS, 13(8), 2017年08月
  • Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12), Kayoko Yoshida; Chiyo K. Imamura; Kanako Hara; Mayumi Mochizuki; Yusuke Tanigawara, METABOLOMICS, 13(8), 2017年08月
  • Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12), Kayoko Yoshida; Chiyo K. Imamura; Kanako Hara; Mayumi Mochizuki; Yusuke Tanigawara, METABOLOMICS, 13(8), 2017年08月
  • Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205), Kohei Shitara; Toshihiko Doi; Osamu Nagano; Chiyo K. Imamura; Takeshi Ozeki; Yuya Ishii; Kenji Tsuchihashi; Shunji Takahashi; Takako E. Nakajima; Shuichi Hironaka; Miki Fukutani; Hiromi Hasegawa; Shogo Nomura; Akihiro Sato; Yasuaki Einaga; Takeshi Kuwata; Hideyuki Saya; Atsushi Ohtsu, GASTRIC CANCER, 20(2):341 - 349, 2017年03月
  • Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205), Kohei Shitara; Toshihiko Doi; Osamu Nagano; Chiyo K. Imamura; Takeshi Ozeki; Yuya Ishii; Kenji Tsuchihashi; Shunji Takahashi; Takako E. Nakajima; Shuichi Hironaka; Miki Fukutani; Hiromi Hasegawa; Shogo Nomura; Akihiro Sato; Yasuaki Einaga; Takeshi Kuwata; Hideyuki Saya; Atsushi Ohtsu, GASTRIC CANCER, 20(2):341 - 349, 2017年03月
  • Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205), Kohei Shitara; Toshihiko Doi; Osamu Nagano; Chiyo K. Imamura; Takeshi Ozeki; Yuya Ishii; Kenji Tsuchihashi; Shunji Takahashi; Takako E. Nakajima; Shuichi Hironaka; Miki Fukutani; Hiromi Hasegawa; Shogo Nomura; Akihiro Sato; Yasuaki Einaga; Takeshi Kuwata; Hideyuki Saya; Atsushi Ohtsu, GASTRIC CANCER, 20(2):341 - 349, 2017年03月
  • Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study, Eisuke Booka; Chiyo K. Imamura; Hiroya Takeuchi; Yasuo Hamamoto; Daisuke Gomi; Takuro Mizukami; Takashi Ichiyama; Kazunari Tateishi; Tsunehiro Takahashi; Hirofumi Kawakubo; Kenzo Soejima; Narikazu Boku; Yusuke Tanigawara; Yuko Kitagawa, GASTRIC CANCER, 19(3):876 - 886, 2016年07月
  • Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study, Eisuke Booka; Chiyo K. Imamura; Hiroya Takeuchi; Yasuo Hamamoto; Daisuke Gomi; Takuro Mizukami; Takashi Ichiyama; Kazunari Tateishi; Tsunehiro Takahashi; Hirofumi Kawakubo; Kenzo Soejima; Narikazu Boku; Yusuke Tanigawara; Yuko Kitagawa, GASTRIC CANCER, 19(3):876 - 886, 2016年07月
  • Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole, Chiyo K. Imamura; Kenichi Furihata; Shinichiro Okamoto; Yusuke Tanigawara, JOURNAL OF CLINICAL PHARMACOLOGY, 56(4):408 - 413, 2016年04月
  • Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole, Chiyo K. Imamura; Kenichi Furihata; Shinichiro Okamoto; Yusuke Tanigawara, JOURNAL OF CLINICAL PHARMACOLOGY, 56(4):408 - 413, 2016年04月
  • カルボプラチン投与量算出におけるCalvert式利用に関する実態調査, 今村 知世; 加藤 有紀子; 下方 智也; 安藤 雄一; 谷川原 祐介, 医療薬学, 41(11):759 - 767, 2015年11月
  • カルボプラチン投与量算出におけるCalvert式利用に関する実態調査, 今村 知世; 加藤 有紀子; 下方 智也; 安藤 雄一; 谷川原 祐介, 医療薬学, 41(11):759 - 767, 2015年11月
  • 制吐薬適正使用ガイドラインに関するアンケート調査, 佐伯 俊昭; 田村 和夫; 相羽 惠介; 青儀 健二郎; 飯野 京子; 今村 知世; 江口 研二; 沖田 憲司; 加賀美 芳和; 田中 竜平; 中川 和彦; 藤井 博文; 朴 成和; 松浦 一生; 和田 信; 明智 龍男; 角道 祐一; 金 容壱; 佐々木 秀法; 志真 泰夫; 武田 真幸; 永崎 栄次郎; 西舘 敏彦; 齊藤 光江; 足利 幸乃; 谷川原 祐介; 平田 公一; 石岡 千加史; 西山 正彦, 癌と化学療法, 42(3):305 - 311, 2015年03月
  • 制吐薬適正使用ガイドラインに関するアンケート調査, 佐伯 俊昭; 田村 和夫; 相羽 惠介; 青儀 健二郎; 飯野 京子; 今村 知世; 江口 研二; 沖田 憲司; 加賀美 芳和; 田中 竜平; 中川 和彦; 藤井 博文; 朴 成和; 松浦 一生; 和田 信; 明智 龍男; 角道 祐一; 金 容壱; 佐々木 秀法; 志真 泰夫; 武田 真幸; 永崎 栄次郎; 西舘 敏彦; 齊藤 光江; 足利 幸乃; 谷川原 祐介; 平田 公一; 石岡 千加史; 西山 正彦, 癌と化学療法, 42(3):305 - 311, 2015年03月
  • Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype, Yuji Miura; Chiyo K. Imamura; Koya Fukunaga; Yoshihiko Katsuyama; Koichi Suyama; Toshikazu Okaneya; Taisei Mushiroda; Yuichi Ando; Toshimi Takano; Yusuke Tanigawara, BMC CANCER, 14, 2014年12月
  • Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype, Yuji Miura; Chiyo K. Imamura; Koya Fukunaga; Yoshihiko Katsuyama; Koichi Suyama; Toshikazu Okaneya; Taisei Mushiroda; Yuichi Ando; Toshimi Takano; Yusuke Tanigawara, BMC CANCER, 14, 2014年12月
  • International models of investigator-initiated trials: implications for Japan, E. L. Trimble; J. Ledermann; K. Law; T. Miyata; C. K. Imamura; B. -H. Nam; Y. H. Kim; Y. -J. Bang; M. Michaels; D. Ardron; S. Amano; Y. Ando; T. Tominaga; K. Kurokawa; N. Takebe, ANNALS OF ONCOLOGY, 23(12):3151 - 3155, 2012年12月
  • International models of investigator-initiated trials: implications for Japan, E. L. Trimble; J. Ledermann; K. Law; T. Miyata; C. K. Imamura; B. -H. Nam; Y. H. Kim; Y. -J. Bang; M. Michaels; D. Ardron; S. Amano; Y. Ando; T. Tominaga; K. Kurokawa; N. Takebe, ANNALS OF ONCOLOGY, 23(12):3151 - 3155, 2012年12月
  • Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies, Prithviraj Bose; Edward B. Perkins; Connie Honeycut; Martha D. Wellons; Tammy Stefan; James W. Jacobberger; Emmanouil Kontopodis; Jan H. Beumer; Merrill J. Egorin; Chiyo K. Imamura; W. Douglas Figg; Judith E. Karp; Omer N. Koc; Brenda W. Cooper; Selina M. Luger; A. Dimitrios Colevas; John D. Roberts; Steven Grant, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6):1657 - 1667, 2012年06月
  • Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies, Prithviraj Bose; Edward B. Perkins; Connie Honeycut; Martha D. Wellons; Tammy Stefan; James W. Jacobberger; Emmanouil Kontopodis; Jan H. Beumer; Merrill J. Egorin; Chiyo K. Imamura; W. Douglas Figg; Judith E. Karp; Omer N. Koc; Brenda W. Cooper; Selina M. Luger; A. Dimitrios Colevas; John D. Roberts; Steven Grant, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(6):1657 - 1667, 2012年06月
  • Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients., Matsuoka H; Arao T; Makimura C; Takeda M; Kiyota H; Tsurutani J; Fujita Y; Matsumoto K; Kimura H; Otsuka M; Koyama A; Imamura CK; Tanigawara Y; Yamanaka T; Tanaka K; Nishio K; Nakagawa, Oncol Rep, 27(5):1393 - 1399, 2012年05月
  • Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients., Matsuoka H; Arao T; Makimura C; Takeda M; Kiyota H; Tsurutani J; Fujita Y; Matsumoto K; Kimura H; Otsuka M; Koyama A; Imamura CK; Tanigawara Y; Yamanaka T; Tanaka K; Nishio K; Nakagawa, Oncol Rep, 27(5):1393 - 1399, 2012年05月
  • A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese., Kazuma Kiyotani; Taisei Mushiroda; Tatsuhiko Tsunoda; Takashi Morizono; Naoya Hosono; Michiaki Kubo; Yusuke Tanigawara; Chiyo K Imamura; David A Flockhart; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Human molecular genetics, 21(7):1665 - 72, 2012年04月
  • A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese., Kazuma Kiyotani; Taisei Mushiroda; Tatsuhiko Tsunoda; Takashi Morizono; Naoya Hosono; Michiaki Kubo; Yusuke Tanigawara; Chiyo K Imamura; David A Flockhart; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Human molecular genetics, 21(7):1665 - 72, 2012年04月
  • Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Yusuke Tanigawara; Naoya Hosono; Michiaki Kubo; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Breast cancer research and treatment, 131(1):137 - 45, 2012年01月
  • Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Yusuke Tanigawara; Naoya Hosono; Michiaki Kubo; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Breast cancer research and treatment, 131(1):137 - 45, 2012年01月
  • Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response to Morphine Treatment in Cancer Patients, Chihiro Makimura; Tokuzo Arao; Hiromichi Matsuoka; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, ANTICANCER RESEARCH, 31(12):4561 - 4568, 2011年12月
  • Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response to Morphine Treatment in Cancer Patients, Chihiro Makimura; Tokuzo Arao; Hiromichi Matsuoka; Masayuki Takeda; Hidemi Kiyota; Junji Tsurutani; Yoshihiko Fujita; Kazuko Matsumoto; Hideharu Kimura; Masatomo Otsuka; Atsuko Koyama; Chiyo K. Imamura; Takeharu Yamanaka; Kyoko Tanaka; Kazuto Nishio; Kazuhiko Nakagawa, ANTICANCER RESEARCH, 31(12):4561 - 4568, 2011年12月
  • How can we address cancer care after a natural disaster?, Chiyo K. Imamura; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 8(7):387 - 388, 2011年07月
  • How can we address cancer care after a natural disaster?, Chiyo K. Imamura; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 8(7):387 - 388, 2011年07月
  • Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Tanigawara; David A Flockhart; Zeruesenay Desta; Todd C Skaar; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(8):1287 - 93, 2010年03月
  • Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients., Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Tanigawara; David A Flockhart; Zeruesenay Desta; Todd C Skaar; Fuminori Aki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(8):1287 - 93, 2010年03月
  • EXPERIMENTAL THERAPIES Investigator-initiated cancer trials with INDs for approval in Japan, Chiyo K. Imamura; Naoko Takebe; Seigo Nakamura; Hideyuki Saya; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 7(3):127 - 128, 2010年03月
  • EXPERIMENTAL THERAPIES Investigator-initiated cancer trials with INDs for approval in Japan, Chiyo K. Imamura; Naoko Takebe; Seigo Nakamura; Hideyuki Saya; Naoto T. Ueno, NATURE REVIEWS CLINICAL ONCOLOGY, 7(3):127 - 128, 2010年03月
  • A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors, Nilofer Azad; Alyssa Perroy; Erin Gardner; Chiyo K. Imamura; Cynthia Graves; Gisele A. Sarosy; Lori Minasian; Herbert Kotz; Miranda Raggio; William D. Figg; Elise C. Kohn, CANCER BIOLOGY & THERAPY, 8(19):1800 - 1805, 2009年10月
  • A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors, Nilofer Azad; Alyssa Perroy; Erin Gardner; Chiyo K. Imamura; Cynthia Graves; Gisele A. Sarosy; Lori Minasian; Herbert Kotz; Miranda Raggio; William D. Figg; Elise C. Kohn, CANCER BIOLOGY & THERAPY, 8(19):1800 - 1805, 2009年10月
  • がん化学療法レジメンのエビデンスとなる臨床論文の副作用特性に基づいた「副作用グレード評価シート」の作成, 今村 知世; 後田 奈緒美; 津田 壮一郎; 谷川原 祐介, 日本病院薬剤師会雑誌, 43(6):796-799, 2007年
  • がん化学療法レジメンのエビデンスとなる臨床論文の副作用特性に基づいた「副作用グレード評価シート」の作成, 今村 知世; 後田 奈緒美; 津田 壮一郎; 谷川原 祐介, 日本病院薬剤師会雑誌, 43(6):796-799, 2007年
  • How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?, CI Kawasaki; R Nishi; S Uekihara; S Hayano; U Kragh-Hansen; CI Kawasaki; M Otagiri, CLINICAL TOXICOLOGY, 43(2):95 - 99, 2005年
  • How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?, CI Kawasaki; R Nishi; S Uekihara; S Hayano; U Kragh-Hansen; CI Kawasaki; M Otagiri, CLINICAL TOXICOLOGY, 43(2):95 - 99, 2005年
  • Comparison of the pharmaceutical properties of sustained-release gel beads prepared by alginate having different molecular size with commercial sustained-release tablet, T Imai; C Kawasaki; T Nishiyama; M Otagiri, PHARMAZIE, 55(3):218 - 222, 2000年03月
  • Comparison of the pharmaceutical properties of sustained-release gel beads prepared by alginate having different molecular size with commercial sustained-release tablet, T Imai; C Kawasaki; T Nishiyama; M Otagiri, PHARMAZIE, 55(3):218 - 222, 2000年03月
  • Charcoal hemoperfusion in the treatment of phenytoin overdose, C Kawasaki; R Nishi; S Uekihara; S Hayano; N Otagiri, AMERICAN JOURNAL OF KIDNEY DISEASES, 35(2):323 - 326, 2000年02月
  • Charcoal hemoperfusion in the treatment of phenytoin overdose, C Kawasaki; R Nishi; S Uekihara; S Hayano; N Otagiri, AMERICAN JOURNAL OF KIDNEY DISEASES, 35(2):323 - 326, 2000年02月
  • 腎移植患者の妊娠・分娩時におけるシクロスポリン濃度, 川崎 知世; 石井 緑; 冨丸 明; 西 玲子; 市丸 俊三; 清田 祐史; 上木原 宗一; 早野 俊一; 井 清司; 松金 秀暢, TDM研究, 14:242-245, 1997年
  • 腎移植患者の妊娠・分娩時におけるシクロスポリン濃度, 川崎 知世; 石井 緑; 冨丸 明; 西 玲子; 市丸 俊三; 清田 祐史; 上木原 宗一; 早野 俊一; 井 清司; 松金 秀暢, TDM研究, 14:242-245, 1997年
  • フェニトイン中毒における活性炭血液吸着法の有用性, 川崎 知世; 古閑 洋子; 西 玲子; 外牧 潤; 上木原 宗一; 早野 俊一; 小田切 優樹, 中毒研究, 10:379-384, 1997年
  • フェニトイン中毒における活性炭血液吸着法の有用性, 川崎 知世; 古閑 洋子; 西 玲子; 外牧 潤; 上木原 宗一; 早野 俊一; 小田切 優樹, 中毒研究, 10:379-384, 1997年
  • 健康成人および出血性潰瘍患者におけるOmeprazole含有坐剤のバイオアベイラビリティについて ―腸溶錠との比較―, 川崎 知世; 西 玲子; 北田 英貴; 小田切 優樹, 臨床薬理, 28:603-608, 1997年
  • 健康成人および出血性潰瘍患者におけるOmeprazole含有坐剤のバイオアベイラビリティについて ―腸溶錠との比較―, 川崎 知世; 西 玲子; 北田 英貴; 小田切 優樹, 臨床薬理, 28:603-608, 1997年
  • Preparation and evaluation of a suppository dosage form containing omeprazole, Kawasaki C; Nishi R; Otagiri M, Pharm. Sci., 3:431-434, 1997年
  • Preparation and evaluation of a suppository dosage form containing omeprazole, Kawasaki C; Nishi R; Otagiri M, Pharm. Sci., 3:431-434, 1997年
  • テオフィリン中毒症例における血液灌流時のテオフィリン血中濃度推移と蛋白結合率の変動, 川崎 知世; 陣上 祥子; 西 玲子; 上木原 宗一; 松金 秀暢; 小田切 優樹, 中毒研究, 9:75-80, 1996年
  • テオフィリン中毒症例における血液灌流時のテオフィリン血中濃度推移と蛋白結合率の変動, 川崎 知世; 陣上 祥子; 西 玲子; 上木原 宗一; 松金 秀暢; 小田切 優樹, 中毒研究, 9:75-80, 1996年

講演・口頭発表等

  • Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity, KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第18回日本臨床腫瘍学会学術集会, 2021年02月18日, Live Streaming
  • 生命倫理審査における臨床薬理の専門性　実施側として審査を受けた経験も踏まえて, 今村　知世, 第40回日本臨床薬理学会学術総会, 2019年12月06日, 東京
  • タモキシフェンpharmacogenomics 研究から学んだこと (ワークショップ4), 今村　知世, 第57回日本癌治療学会学術集会, 2019年10月24日, 福岡
  • Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT., HIRATA Kenro;HAMAMOTO Yasuo;TSUCHIHASHI Kenji;KONDOH Chihiro;YAMAZAKI Kentaro;HIRONAKA Syuichi;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;MURO Kei, ESMO Congress 2019, 2019年09月27日, Barcelona
  • 肝機能低下患者への抗がん薬投与 ～評価指標と推奨用量のエビデンス～ (シンポジウム18 がん薬物治療における慎重投与例への対応), 今村　知世, 第17回日本臨床腫瘍学会学術集会, 2019年07月20日, 京都
  • Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC, IMAMURA Chiyo K.;KENMOTSU Hirotsugu;KAWAMURA Takahisa;OYAKAWA Takuya;ONO Akira;OMORI Shota;NAKASHIMA Kazutoshi;WAKUDA Kazushige;TAIRA Tetsuhiko;NAITO Tateaki;MURAKAMI Haruyasu;YAMAMOTO Nobuyuki;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第17回日本臨床腫瘍学会学術集会, 2019年07月19日, 京都
  • Exposure-response analysis of S-1 in patients with advanced gastric cancer, TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;KASAI Hidefumi;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, 第17回日本臨床腫瘍学会学術集会, 2019年07月18日, 京都
  • スペシャル・ポピュレーション（腎機能低下、肝機能低下、高齢者）へのがん薬物療法 Part 2, 今村　知世, 第52回がんプロセミナー（7大学連携個別化がん医療実践者養成プラン）, 2019年04月24日, 狭山
  • Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer, SATAKE Hironaga;SUZUKI Takeshi;IMAMURA Chiyo K.;SUKAWA Yasutaka;MASUISHI Toshiki;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, AACR Annual Meeting 2019, 2019年04月02日, Atlanta

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.